Category - Feature

Feature

Harvard Apparatus to file IND for regenerated trachea trial

By Len Zehr Harvard Apparatus Regenerative Technology (NASDAQ:HART) plans to file an IND later this year for a pivotal trial of the world’s first regenerated trachea transplant in patients facing life-threatening...

January 13, 2015

Feature

Season’s Greetings (and JPM 2015)

Wow! What a great year 2014 turned out to be! On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will...

December 19, 2014

Feature

Avivagen’s OxC-beta as natural alternative to antibiotics

By Len Zehr Three peer-reviewed research papers published this year by Avivagen (TSX-V:VIV) and independent collaborators, backed up with successful testing in Asia, have put the company in a position to pursue major...

December 9, 2014

Feature

Nuvo Research to release Phase 2 WF10 data in Q1

By Len Zehr Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing...

December 2, 2014

Feature

Ruthigen nears clinical milestone with anti-infective drug

By Len Zehr Ruthigen (NASDAQ:RTGN) expects to complete enrollment at the end of the year of the first 20 patients, representing the first arm of the Phase 1/2 clinical trial of RUT58-60, which is intended for use as an...

November 25, 2014

Feature

Tandem takes consumer device approach to insulin pumps

By Len Zehr Tandem Diabetes (NASDAQ:TNDM), which now markets the popular t:slim Insulin Pump for people with Type 1 diabetes and has two new pumps awaiting FDA clearance, has taken a unique consumer-focused approach to...

November 18, 2014

Feature

rEVO Biologics spearheading preeclampsia treatment

By Len Zehr Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the...

November 11, 2014

Feature

CytoTools awaiting India clearance for DermaPro

By Len Zehr CytoTools AG (DE000A0KFRJ1/T5O) of Germany and its Indian marketing partner, Centaur Pharmaceuticals, expect to receive regulatory clearance in the current quarter in India for lead product, DermaPro, to...

November 4, 2014

Feature

AD focus shifts to treating agitation/aggression

By Len Zehr After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric...

October 28, 2014

Feature

Stellar Biotechnologies harvests mollusks for KLH protein

By Len Zehr A mollusk living in the coastal waters off California from Monterey to the Baja Peninsula may hold the key to new therapies to treat cancer and autoimmune diseases. Stellar Biotechnologies (OTCQB:SBOTF; TSX...

October 21, 2014

Category - Feature

Harvard Apparatus to file IND for regenerated trachea trial

Season’s Greetings (and JPM 2015)

Avivagen’s OxC-beta as natural alternative to antibiotics

Nuvo Research to release Phase 2 WF10 data in Q1

Ruthigen nears clinical milestone with anti-infective drug

Tandem takes consumer device approach to insulin pumps

rEVO Biologics spearheading preeclampsia treatment

CytoTools awaiting India clearance for DermaPro

AD focus shifts to treating agitation/aggression

Stellar Biotechnologies harvests mollusks for KLH protein

General

More